CellectisのIPO年
CellectisのIPO年は何ですか。
CellectisのIPO年は2015です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
NASDAQのセクタHealth CareにおけるIPO年の企業と比べるCellectis
Cellectisは何をしますか。
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Cellectisと類似のipo年
- Global BrandsのIPO年は2014です。
- Antibe TherapeuticsのIPO年は2014です。
- ArcelorMittal 5.50% MandatorilyのIPO年は2014です。
- The Toronto-Dominion Bank PFD SER 5のIPO年は2014です。
- WisdomTree EURO STOXX Banks 3x Daily LeveragedのIPO年は2014です。
- Horizons Us Lrg Cap Eqty Cvrd CのIPO年は2014です。
- CellectisのIPO年は2015です。
- Larsen & Toubro InfotechのIPO年は2016です。
- Escape Hunt plcのIPO年は2016です。
- SiteOne Landscape Supply IncのIPO年は2016です。
- Lloyds Steels IndustriesのIPO年は2016です。
- Liberty MediaのIPO年は2016です。
- Atlanta Braves IncのIPO年は2016です。